Gilbert Desmangles, MD
Family Medicine · Plattsburgh, NYNPI 1285738278
Payments from drug & device makers
Across 543 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- AstraZeneca$1K
- GSK$972
- Lilly USA, LLC$619
- Amgen$600
- plus $3K from 27 others
What the payments were for
- Food & beverage$9,29399%
- Education$681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 90 | $1,468 |
| AbbVie(2 entities) | 86 | $1,438 |
| AstraZeneca | 65 | $1,224 |
| GSK | 62 | $972 |
| Lilly USA, LLC | 45 | $619 |
| Amgen | 34 | $600 |
| Pfizer | 24 | $426 |
| Boehringer Ingelheim | 14 | $315 |
| Otsuka America Pharmaceutical, Inc. | 19 | $261 |
| Sanofi-aventis U.S. LLC | 13 | $223 |
| Johnson & Johnson | 11 | $213 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $204 |
| Astellas Pharma US Inc | 6 | $163 |
| Novartis | 9 | $155 |
| Baxter Healthcare | 3 | $145 |
| Abbott | 7 | $127 |
| E.r. Squibb & Sons, L.L.C. | 6 | $102 |
| Lundbeck LLC | 4 | $99 |
| Merck | 6 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| Biohaven Pharmaceuticals, Inc. | 4 | $75 |
| Dexcom, Inc. | 3 | $60 |
| Collegium Pharmaceutical, Inc. | 3 | $50 |
| Exact Sciences | 2 | $47 |
| Amarin Pharma, Inc. | 2 | $38 |
| Circassia Inc. | 2 | $35 |
| Viatris Specialty LLC | 1 | $29 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
How this compares
$9,361 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $154,425 |
| TrulicityDulaglutide | 85 | $148,398 |
| OzempicSemaglutide | 48 | $103,521 |
| JardianceEmpagliflozin | 62 | $90,180 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $36,591 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $30,526 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $25,425 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $22,450 |
| MounjaroTirzepatide | 16 | $22,121 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $19,878 |
| FarxigaDapagliflozin Propanediol | 12 | $17,852 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $16,603 |
| RybelsusSemaglutide | 12 | $13,282 |
| MyrbetriqMirabegron | 14 | $12,607 |
| InvokametCanagliflozin/Metformin Hcl | 11 | $11,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $619 | $170,519101 claims |
| PfizerEliquis | $426 | $154,425109 claims |
| Novo NordiskOzempic, Rybelsus | $1,468 | $116,80360 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $315 | $101,58378 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $972 | $69,910105 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $1,224 | $48,37830 claims |
| Astellas Pharma US IncMyrbetriq | $163 | $12,60714 claims |
| Johnson & JohnsonInvokamet | $213 | $11,93611 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $50 | $6,21311 claims |
| MerckDulera | $79 | $3,99011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Plattsburgh
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.